German drugmaker Boehringer eyes Japan as Asia hub with $346m investment

Production of key diabetes treatment aims to meet growing demand across region

20250619 Boehringer Ingelheim next Chairman of the Board of Managing Directors Shashank Deshpande

Shashank Deshpande, who is set to become Boehringer Ingelheim's board chairman in July, spoke with Nikkei Asia recently about the German drugmaker's manufacturing plans in Japan. (Nikkei montage/Source photos by Reuters and Sayumi Take)

YURIKA YONEDA

June 20, 2025 14:39 JST

TOKYO -- German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base for Asia and Oceania.